Lumacaftor/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles.
Ikrame ChouchaneNathalie Stremler-LebelPhilippe ReixPublished in: Clinical case reports (2019)
We report the initiation of CFTR modulator lumacaftor/ivacaftor combination (LUM/IVA) in two adolescents with cystic fibrosis who were treated with antifungal azoles (AZO) and tacrolimus (TCS) for liver transplantation. Despite multiple drug-drug interactions, maintaining therapeutic TCS levels was achievable. During the following year, LUM/IVA was well tolerated, providing clinical benefits.